MetLife Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.7M | Buy |
304,172
+456
| +0.2% | +$23.2K | 0.08% | 240 |
|
|
2025
Q4 | $15.1M | Buy |
303,716
+271,488
| +842% | +$13.2M | 0.07% | 246 |
|
|
2025
Q3 | $1.54M | Hold |
32,228
| – | – | 0.01% | 1231 |
|
|
2025
Q2 | $1.02M | Buy |
32,228
+1,895
| +6% | +$60.7K | 0.01% | 1307 |
|
|
2025
Q1 | $993K | Sell |
30,333
-489
| -2% | -$17.3K | 0.01% | 1370 |
|
|
2024
Q4 | $1.11M | Buy |
30,822
+1,394
| +5% | +$49.1K | 0.01% | 1356 |
|
|
2024
Q3 | $918K | Hold |
29,428
| – | – | 0.01% | 1436 |
|
|
2024
Q2 | $787K | Buy |
29,428
+3,423
| +13% | +$99.2K | ﹤0.01% | 1477 |
|
|
2024
Q1 | $887K | Hold |
26,005
| – | – | 0.01% | 1366 |
|
|
2023
Q4 | $753K | Hold |
26,005
| – | – | 0.01% | 1453 |
|
|
2023
Q3 | $717K | Hold |
26,005
| – | – | 0.01% | 1416 |
|
|
2023
Q2 | $782K | Hold |
26,005
| – | – | 0.01% | 1407 |
|
|
2023
Q1 | $942K | Hold |
26,005
| – | – | 0.01% | 1247 |
|
|
2022
Q4 | $928K | Sell |
26,005
-834
| -3% | -$29K | 0.01% | 1258 |
|
|
2022
Q3 | $909K | Sell |
26,839
-1,030
| -4% | -$33.5K | 0.01% | 1241 |
|
|
2022
Q2 | $806K | Hold |
27,869
| – | – | 0.01% | 1333 |
|
|
2022
Q1 | $901K | Buy |
27,869
+9,872
| +55% | +$303K | 0.01% | 1400 |
|
|
2021
Q4 | $525K | Hold |
17,997
| – | – | ﹤0.01% | 1481 |
|
|
2021
Q3 | $480K | Hold |
17,997
| – | – | ﹤0.01% | 1543 |
|
|
2021
Q2 | $554K | Sell |
17,997
-4,497
| -20% | -$138K | ﹤0.01% | 1507 |
|
|
2021
Q1 | $589K | Hold |
22,494
| – | – | 0.01% | 1429 |
|
|
2020
Q4 | $566K | Hold |
22,494
| – | – | 0.01% | 1427 |
|
|
2020
Q3 | $469K | Hold |
22,494
| – | – | 0.01% | 1397 |
|
|
2020
Q2 | $534K | Hold |
22,494
| – | – | 0.01% | 1340 |
|
|
2020
Q1 | $405K | Hold |
22,494
| – | – | 0.01% | 1324 |
|
|
2019
Q4 | $534K | Hold |
22,494
| – | – | 0.01% | 1431 |
|
|
2019
Q3 | $618K | Hold |
22,494
| – | – | 0.01% | 1307 |
|
|
2019
Q2 | $744K | Hold |
22,494
| – | – | 0.01% | 1257 |
|
|
2019
Q1 | $788K | Hold |
22,494
| – | – | 0.01% | 1190 |
|
|
2018
Q4 | $747K | Hold |
22,494
| – | – | 0.01% | 1139 |
|
|
2018
Q3 | $1.13M | Hold |
22,494
| – | – | 0.01% | 1072 |
|
|
2018
Q2 | $1.35M | Buy |
22,494
+1,022
| +5% | +$52.9K | 0.02% | 916 |
|
|
2018
Q1 | $983K | Hold |
21,472
| – | – | 0.01% | 1016 |
|
|
2017
Q4 | $856K | Buy |
+21,472
| New | +$848K | 0.01% | 1096 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
MetLife Investment Management's SUPN Position: Q1 2026 in Review
MetLife Investment Management increased its Supernus Pharmaceuticals (SUPN) stake by 0.15% in Q1 2026, buying an estimated $23.2K and bringing the position to 304,172 shares worth $15.7M. The position accounts for 0.08% of the portfolio, ranked #240.
MetLife Investment Management first reported a position in SUPN in Q4 2017 and has held it in 34 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- MetLife Investment Management held 304,172 shares of Supernus Pharmaceuticals worth $15.7M as of Q1 2026.
- MetLife Investment Management bought 456 Supernus Pharmaceuticals shares in Q1 2026, an estimated $23.2K.
- Supernus Pharmaceuticals made up 0.08% of MetLife Investment Management's portfolio in Q1 2026, its #240 holding.
- MetLife Investment Management first reported a position in Supernus Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.